Needlescopic-assisted Uniportal vs Uniportal VATS (UNeed)
Needlescopic-assisted Uniportal VATS Versus Conventional Uniportal VATS. A Randomized Prospective Noninferiority Study
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment (Actual)
Enrollment
Phase
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
Hsin-Chu County
-
Taipei, Hsin-Chu County, Taiwan, 30059
- National Taiwan University Hospital, Hsin-Chu Branch
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Lung or mediastinal disease requiring thoracoscopic surgery
Exclusion Criteria:
Thoracoscopic esophagectomy Decortication for empyema
Study Plan
How is the study designed?
Design Details
- Primary Purpose: TREATMENT
- Allocation: RANDOMIZED
- Interventional Model: PARALLEL
- Masking: SINGLE
Number of Arms
Arms and Interventions
Participant Group / ArmParticipant Group / Arm |
Intervention / TreatmentIntervention / Treatment |
|---|---|
|
Experimental: Needlescopic-assisted
Thoracoscopic surgery performed with the fashion of single 2.5-3.5 cm intercostal incision and 1-2 additional 2-3 mmm needlescopic ports.
|
Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.
|
|
Active Comparator: Uniportal
Conventional uniportal VATS with single 2.5-3.5 cm intercostal incision
|
Video-assisted thoracoscopic surgery for pulmonary or mediastinal lesions.
|
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Pain scale POD 3
Time Frame: 3 days
|
Post-operative day 3 pain scale documented using Visual Analogue Scale (VAS)
|
3 days
|
|
Pain scale POD 5
Time Frame: 5 days
|
Post-operative day 5 pain scale documented using Visual Analogue Scale (VAS)
|
5 days
|
|
Hospital stay
Time Frame: 14 days
|
Post-operative hospital stay
|
14 days
|
|
Post-operative 3 month neuralgia
Time Frame: 3 months
|
Out patient documented using PainDETECT questionnaire (PD-Q)
|
3 months
|
|
Post-operative 6 month neuralgia
Time Frame: 6 months
|
Out patient documented using PainDETECT questionnaire (PD-Q)
|
6 months
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cost
Time Frame: 14 days
|
Total hospital cost
|
14 days
|
|
Surgical time
Time Frame: 1 day
|
Time spend in surgery
|
1 day
|
|
Surgical bleeding
Time Frame: 1 day
|
Blood loss during operation
|
1 day
|
|
Opioid using dosage
Time Frame: 14 days
|
Total opioid equivalent dose used during post-operative course
|
14 days
|
Collaborators and Investigators
Sponsor
Sponsor
Investigators
Investigators
- Principal Investigator: Chiu-kuei Nien, National Taiwan University Hospital Hsinchu branch
Study record dates
Study Major Dates
Study Start (Actual)
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Actual)
First Posted
Study Record Updates
Last Update Posted (Actual)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
Other Study ID Numbers
- 106-067-F
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Lung Cancer
-
NCT04789681RecruitingStage III Lung Cancer AJCC v8 | Lung Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8
-
NCT04067830RecruitingStage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer AJCC v8
-
NCT03731585Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8
-
NCT03686007Active, not recruitingCaregiver | Stage III Lung Cancer AJCC v7 | Stage I Lung Cancer AJCC v7 | Stage II Lung Cancer AJCC v7 | Stage IB Lung Cancer AJCC v7 | Stage IA Lung Cancer AJCC v7 | Stage IIA Lung Cancer AJCC v7 | Stage IIB Lung Cancer AJCC v7 | Stage IIIA Lung Cancer AJCC v7 | Stage IIIB Lung Cancer AJCC v7
-
NCT05340309Active, not recruitingStage IVA Lung Cancer AJCC v8 | Stage IVB Lung Cancer AJCC v8 | Lung Non-Small Cell Carcinoma | Stage III Lung Cancer AJCC v8 | Stage IV Lung Cancer AJCC v8 | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage IIIB Lung Cancer AJCC v8
-
NCT04348292TerminatedLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer AJCC v8
-
NCT04061590WithdrawnLung Non-Small Cell Carcinoma | Stage II Lung Cancer AJCC v8 | Stage IIA Lung Cancer AJCC v8 | Stage IIB Lung Cancer AJCC v8 | Stage IIIA Lung Cancer AJCC v8 | Stage I Lung Cancer AJCC v8 | Stage IA1 Lung Cancer AJCC v8 | Stage IA2 Lung Cancer AJCC v8 | Stage IA3 Lung Cancer AJCC v8 | Stage IB Lung Cancer AJCC v8
-
NCT05281237RecruitingLung Cancer | Lung Cancer Stage I | Lung Cancer Stage II | Stage I Lung Cancer | Stage I - II Primary Lung Cancer | Stage II Lung Cancer
-
NCT04069936TerminatedNSCLC | Lung Cancer | Lung Cancer Metastatic | Lung Cancer, Non-small Cell | Non Small Cell Lung Cancer | Non-small Cell Lung Cancer | Non-small Cell Lung Cancer Metastatic | Non Small Cell Lung Cancer Metastatic
-
NCT06654245TerminatedStage IV Lung Cancer | Stage III Lung Cancer | Stage I Lung Cancer | Stage II Lung Cancer
Clinical Trials on Thoracoscopic surgery
-
NCT05034640CompletedThoracic Diseases | Thoracic Surgery | Pediatric Disorder | Pneumothorax, Spontaneous
-
NCT04212481RecruitingSingle-port Video-assisted Thoracoscopic Surgery
-
NCT02033772CompletedCongenital Diaphragmatic Hernia | Esophageal Atresia | Tracheoesophageal Fistula
-
NCT00615849CompletedPrimary Spontaneous Pneumothorax
-
NCT05991570Not yet recruiting
-
NCT06391788RecruitingMinimally Invasive Surgery | Cardiomyopathy, Hypertrophic Obstructive
-
NCT06848751RecruitingSurgery | Lung Function Decreased
-
NCT02558608Unknown
-
NCT05840029Active, not recruitingOvarian Cancer
-
NCT01102517Unknown